Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389030%3A_____%2F16%3A00459800" target="_blank" >RIV/61389030:_____/16:00459800 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/61989592:15310/16:33161054
Výsledek na webu
<a href="http://dx.doi.org/10.3892/or.2016.4614" target="_blank" >http://dx.doi.org/10.3892/or.2016.4614</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/or.2016.4614" target="_blank" >10.3892/or.2016.4614</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells
Popis výsledku v původním jazyce
Anaplastic thyroid carcinoma (ATC) is an extremely aggressive human malignancy characterized by a marked degree of invasiveness, absense of features of thyroid differentiation and resistance to current medical treatment. It is well known that ATCs are characterized by deregulation of genes related to cell cycle regulation, i.e., cyclin-dependent kinases (CDKs) and endogenous cyclin-dependent kinase inhibitors (CDKIs). Therefore, in the present study, the effect of a novel exogenous cyclin-dependent kinase inhibitor, BP-14, was investigated in three human ATC cell lines. The ATC-derived cell lines FRO, SW1736 and 8505C were treated with BP-14 alone or in combination with the mTOR inhibitor everolimus. In all ATC cell lines, treatment with BP-14 decreased cell viability and, in two of them, BP-14 modified expression of genes involved in epithelial-mesenchymal transition. Thus, our data indicate that BP-14 is a potential new compound effective against ATC. Combined treatment with BP-14 and the mTOR inhibitor everolimus had a strong synergistic effect on cell viability in all three cell lines, suggesting that the combined used of CDK and mTOR inhibitors may be a useful strategy for ATC treatment.
Název v anglickém jazyce
Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells
Popis výsledku anglicky
Anaplastic thyroid carcinoma (ATC) is an extremely aggressive human malignancy characterized by a marked degree of invasiveness, absense of features of thyroid differentiation and resistance to current medical treatment. It is well known that ATCs are characterized by deregulation of genes related to cell cycle regulation, i.e., cyclin-dependent kinases (CDKs) and endogenous cyclin-dependent kinase inhibitors (CDKIs). Therefore, in the present study, the effect of a novel exogenous cyclin-dependent kinase inhibitor, BP-14, was investigated in three human ATC cell lines. The ATC-derived cell lines FRO, SW1736 and 8505C were treated with BP-14 alone or in combination with the mTOR inhibitor everolimus. In all ATC cell lines, treatment with BP-14 decreased cell viability and, in two of them, BP-14 modified expression of genes involved in epithelial-mesenchymal transition. Thus, our data indicate that BP-14 is a potential new compound effective against ATC. Combined treatment with BP-14 and the mTOR inhibitor everolimus had a strong synergistic effect on cell viability in all three cell lines, suggesting that the combined used of CDK and mTOR inhibitors may be a useful strategy for ATC treatment.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
EB - Genetika a molekulární biologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/GA15-15264S" target="_blank" >GA15-15264S: Cílený transport purinových inhibitorů cyklin-dependentních kinas do nádorových buněk</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Oncology Reports
ISSN
1021-335X
e-ISSN
—
Svazek periodika
35
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
6
Strana od-do
2413-2418
Kód UT WoS článku
000371947700060
EID výsledku v databázi Scopus
—